For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and Attruby represents a true breakthrough . These novel therapies preserve the transthyretin protein, halting its destructive build-up and lessening the severity of the illness. Patients are now reporting benefits in their well… Read More